Research Article
Haptoglobin Gene Polymorphism among Sickle Cell Patients in West Cameroon: Hematological and Clinical Implications
Table 7
Some manifestations of the severity of SCD according to the Hp genotype in SS patients.
| | Parameters | | Hp 1S-1S | Hp 1F-1 F | Hp 1S-1 F | Hp 2-1S | Hp 2-1F | Hp 2-2 | value |
| | VOC | 0 | 5 (20.8%) | 0 (0.0%) | 0 (0.0%) | 1 (9.1%) | 0 (0.0%) | 4 (7.7%) | 0.353ɸ | | 1-2 | 10 (41.7%) | 1 (16.7%) | 1 (100%) | 3 (27.3%) | 1 (25%) | 25 (48.1%) | | | 3 and above | 9 (37.5%) | 5 (83.3%) | 0 (0.0%) | 7 (63.6%) | 3 (75%) | 23 (44.2%) | |
| | Hospitalization | 0 | 8 (33.3%) | 1 (16.7%) | 0 (0.0%) | 5 (45.5%) | 1 (25%) | 20 (37.7%) | 0.756ɸ | | 1 | 10 (41.7%) | 2 (33.3%) | 1 (100%) | 5 (45.5%) | 1 (25%) | 19 (35.8%) | | | 2 and above | 6 (25%) | 3 (50%) | 0 (0.0%) | 1 (9.1%) | 2 (50%) | 14 (26.4%) | |
| | Transfusion | 0 | 12 (50%) | 4 (66.7%) | 1 (100%) | 8 (72.7%) | 3 (75%) | 29 (54.7%) | 0.667ɸ | | 1 and above | 12 (50%) | 2 (33.3%) | 0 (0.0%) | 3 (27.3%) | 1 (25%) | 24 (45.3%) | |
| | Anemia | yes | 23 (95.8%) | 4 (66.7%) | 1 (100%) | 11 (100%) | 4 (100%) | 53 (96.4%) | 0.055ɸ | | no | 1 (4.2%) | 2 (33.3%) | 0 (0.0%) | 0 (0%) | 0 (0%) | 2 (3.6%) | |
| | Anemia severitya | Severe | 11 (47.8%) | 3 (75%) | 0 (0.0%) | 3 (27.3%) | 1 (25%) | 18 (34%) | | | Moderate | 11 (47.8%) | 1 (25%) | 1 (100%) | 8 (72.7%) | 3 (75%) | 33 (62.3%) | 0.803ɸ | | Mild | 1 (4.3%) | 0 (0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (3.7%) | |
| | Type of anemiab | Macrocytic | 16 (69.6%) | 2 (50%) | 1 (100%) | 5 (45.5%) | 2 (50%) | 29 (55.8%) | | | Normocytic | 6 (26.1%) | 2 (50%) | 0 (0.0%) | 5 (45.5%) | 2 (50%) | 19 (36.5%) | 0.948ɸ | | Microcytic | 1 (4.3%) | 0 (0%) | 0 (0.0%) | 1 (9.0%) | 0 (0.0%) | 4 (7.7%) | |
| | Type of hyperleucocytosisc | Moderate | 9 (40.9%) | 2 (33.3%) | 1 (100%) | 3 (27.3%) | 3 (75%) | 20 (40%) | | | Plain | 6 (27.3%) | 2 (33.3%) | 0 (0.0%) | 6 (54.5%) | 0 (0.0%) | 15 (30%) | 0.711ɸ | | Severe | 7 (31.8%) | 2 (33.3%) | 0 (0.0%) | 2 (18.2%) | 1 (25%) | 15 (30%) | |
| | CRP | Negative | 17 (73.9%) | 2 (50%) | 1 (100%) | 7 (63.6%) | 1 (25%) | 18 (39.1%) | 0.071ɸ | | Positive | 6 (26.1%) | 2 (50%) | 0 (0.0%) | 4 (36.4%) | 3 (75%) | 28 (60.9%) | | | BMI (m/kg2) | | 16.60 ± 2.70 | 17.13 ± 3.67 | 14.0 | 16.99 ± 1.60 | 14.90 ± 0.57 | 17.14 ± 2.82 | 0.550α |
|
|
VOC: number of vaso-occlusive crisis (VOC) in one year; hospitalization: number of hospitalizations in one year; transfusion: number of sanguine transfusions in one year; a: severe anemia: Hb < 7 g/dL, moderated anemia: 7 g/dL ≤ Hb < 9 g/dL, mild anemia: 9 g/dL ≤ Hb < 11 g/dL; b: macrocytic anemia: MCV > 90 fL, normocytic anemia: 80 fL ≤ MCV ≤ 90 fL, microcytic anemia: MCV < 80 fL; c: moderate hyperleucocytosis: 10 ×10 9/L < WBC > 15 ×10 9/L, plain hyperleucocytosis: 15×109/L ≤ WBC ≥ 20×109/L, severe hyperleucocytosis: WBC > 20 ×109/L; CRP: C-rective protein; BMI: body mass index; ɸ: chi2 test with the Bonferroni adjustment and Fischer test; α: ANOVA test.
|
